Stock DGXQUEST DIAGNOSTICS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Quest Diagnostics Incorporated Share Price

Equities

DGX

US74834L1008

Healthcare Facilities & Services

Market Closed - Nyse
Other stock markets
 21:10:00 18/06/2025 BST 		5-day change 1st Jan Change
179.78 USD +0.46% Intraday chart for Quest Diagnostics Incorporated +1.58% +19.17%
06-10 Quest Diagnostics to Develop Multi-Cancer Stratification Blood Test Based on Md Anderson Technology CI
06-05 PreciseDx, Inc. announced that it has received $11.230074 million in funding from Eventide Asset Management, LLC, Merck Global Health Innovation Fund, LLC, Philips Venture Capital Fund BV, Labcorp Holdings Inc., Quest Diagnostics Incorporated, GenHenn Capital CI

Valuation: Quest Diagnostics Incorporated

Capitalization 20.07B 17.42B 16.4B 14.9B 27.46B 1,734B 30.78B 193B 74.4B 793B 75.31B 73.71B 2,902B P/E ratio 2025 *
21.1x
P/E ratio 2026 * 19.2x
Enterprise value 25.58B 22.21B 20.9B 18.99B 35B 2,210B 39.22B 245B 94.82B 1,011B 95.98B 93.94B 3,699B EV / Sales 2025 *
2.37x
EV / Sales 2026 * 2.24x
Free-Float
67.83%
Yield 2025 *
1.68%
Yield 2026 * 1.74%
More valuation ratios * Estimated data

Chart: Quest Diagnostics Incorporated

Dynamic Chart

Latest news: Quest Diagnostics Incorporated

Quest Diagnostics to Develop Multi-Cancer Stratification Blood Test Based on Md Anderson Technology 06-10 CI
PreciseDx, Inc. announced that it has received $11.230074 million in funding from Eventide Asset Management, LLC, Merck Global Health Innovation Fund, LLC, Philips Venture Capital Fund BV, Labcorp Holdings Inc., Quest Diagnostics Incorporated, GenHenn Capital 06-05 CI
Quest Diagnostics Incorporated Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10:00 AM 06-03
Quest Diagnostics Insider Sold Shares Worth $306,800, According to a Recent SEC Filing 05-14 MT
Qiagen Q1 Adjusted Earnings, Revenue Rise; New $500 Million Stock Buyback Planned 05-07 MT
JPMorgan Adjusts Price Target on Quest Diagnostics to $190 From $180, Maintains Neutral Rating 05-06 MT
Privia Health Group, Inc. : Beginning of a new cycle 05-01Our Logo
Labcorp beats quarterly profit estimate on diagnostic test demand 04-29 RE
Piper Sandler Adjusts Price Target on Quest Diagnostics to $200 From $180, Maintains Neutral Rating 04-28 MT
Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010. 04-23 CI
Morgan Stanley Adjusts Quest Diagnostics Price Target to $182 From $172, Maintains Overweight Rating 04-23 MT
Baird Adjusts Quest Diagnostics Price Target to $194 From $191, Maintains Outperform Rating 04-23 MT
Jefferies Adjusts Quest Diagnostics Price Target to $195 From $190, Maintains Buy Rating 04-23 MT
More news

Last Transcript: Quest Diagnostics Incorporated

Logo Quest Diagnostics Incorporated
Quest Diagnostics Incorporated Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10:00 AM
06-03
More transcripts

Analysts' recommendations: Quest Diagnostics Incorporated

JPMorgan Adjusts Price Target on Quest Diagnostics to $190 From $180, Maintains Neutral Rating 05-06 MT
Piper Sandler Adjusts Price Target on Quest Diagnostics to $200 From $180, Maintains Neutral Rating 04-28 MT
Morgan Stanley Adjusts Quest Diagnostics Price Target to $182 From $172, Maintains Overweight Rating 04-23 MT
Baird Adjusts Quest Diagnostics Price Target to $194 From $191, Maintains Outperform Rating 04-23 MT
Jefferies Adjusts Quest Diagnostics Price Target to $195 From $190, Maintains Buy Rating 04-23 MT
More recommendations

Press Releases: Quest Diagnostics Incorporated

Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology 06-10 PR
More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals 05-20 PR
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference 05-16 PR
Quest Diagnostics Declares Quarterly Cash Dividend 05-14 PR
Quest Diagnostics Incorporated : First Quarter 2025 View Transcript of Company Prepared Comments 04-22 PU
More press releases

News in other languages: Quest Diagnostics Incorporated

RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU: Tesla, Constellations Brands, Old Dominion, Stellantis, Lloyds... 05/07/24
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK: Ecolab, Texas Instruments, Cisco, Britvic, Shopify... 16/05/24
RECOMENDACIONES DE LOS ANALISTAS EE.UU.: Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... 21/02/24
RECOMENDACIONES DE LOS ANALISTAS EE.UU.: Caterpillar, Eli Lilly, Intel, Caterpillar, Shopify, Snap, Meta, T-Mobile... 07/02/24
Recomendaciones de los analistas EE.UU./UK: Burberry Group, Blackrock, Deliveroo, Unitedhealth, JPMorgan Chase, Qualcomm, Sage... 15/01/24
More news

Quotes and Performance

1 day+0.46%
1 week+1.58%
Current month+3.72%
1 month+1.02%
3 months+4.25%
6 months+18.86%
Current year+19.17%
More quotes

Course Extremes

1 week 177.71
Extreme 177.7102
 182.38
1 month 168.46
Extreme 168.46
 182.38
Current year 148.7
Extreme 148.7
 182.38
1 year 135.47
Extreme 135.47
 182.38
3 years 119.59
Extreme 119.59
 182.38
5 years 103.26
Extreme 103.26
 182.38
10 years 59.66
Extreme 59.655
 182.38
More quotes

Managers and Directors: Quest Diagnostics Incorporated

Manager TitleAgeSince
James Davis CEO
 Chief Executive Officer 62 02/02/2022
Sam Samad DFI
 Director of Finance/CFO 55 10/07/2022
Kristin Wallace CMP
 Compliance Officer - 31/07/2022
Director TitleAgeSince
Gary Pfeiffer BRD
 Director/Board Member 75 30/11/2004
Timothy Ring BRD
 Director/Board Member 67 06/12/2011
James Davis CHM
 Chairman 62 31/03/2023
More insiders

ETFs: Quest Diagnostics Incorporated

Name Weight AuM 1st Jan change
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
14.84% 378 M€ -1.30% -
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED ETF First Trust AlphaDEX U.S. Health Care Sector Index ETF - CAD Hedged
2.17% 3 M€ -4.30% -
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD ETF First Trust AlphaDEX U.S. Health Care Sector Index ETF - CAD
2.05% 6 M€ 0.00% -
More ETFs: Quest Diagnostics Incorporated

Other Healthcare Facilities & Services

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
+0.46%+1.58%+30.94%+37.61% 19.98B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+1.18%+2.52%+10.63%+117.71% 89.6B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-0.37%+1.70%+9.56%-24.61% 84.87B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-2.26%-4.39%+46.84%+45.47% 27.92B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
-2.04%-7.12%-16.67%+17.88% 22.86B
LABCORP HOLDINGS INC. Stock Labcorp Holdings Inc.
+0.75%+0.55%+26.58%+15.55% 21.72B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
-1.37%-5.89%+27.16%-5.68% 15.99B
TENET HEALTHCARE CORPORATION Stock Tenet Healthcare Corporation
+0.07%+3.82%+21.87%+216.49% 15.55B
REDE D'OR SÃO LUIZ S.A. Stock Rede D'Or São Luiz S.A.
-0.62%-0.14%+34.62%+17.02% 14.29B
MAX HEALTHCARE INSTITUTE LIMITED Stock Max Healthcare Institute Limited
-3.53%-0.28%+30.98%+229.77% 13.79B
Average -0.77%+0.62%+22.25%+66.72% 32.66B
Weighted average by Cap. -0.27%+1.63%+17.09%+54.86%
See all sector performances

Financials

2025 *2026 *
Net sales 10.79B 9.37B 8.82B 8.01B 14.77B 933B 16.55B 104B 40.01B 427B 40.5B 39.64B 1,561B 11.23B 9.75B 9.18B 8.34B 15.37B 971B 17.22B 108B 41.64B 444B 42.15B 41.25B 1,624B
Net income 973M 845M 795M 723M 1.33B 84.13B 1.49B 9.34B 3.61B 38.48B 3.65B 3.58B 141B 1.07B 929M 874M 794M 1.46B 92.47B 1.64B 10.26B 3.97B 42.3B 4.01B 3.93B 155B
Net Debt 5.51B 4.78B 4.5B 4.09B 7.54B 476B 8.45B 52.84B 20.42B 218B 20.67B 20.23B 797B 5.12B 4.45B 4.18B 3.8B 7.01B 442B 7.85B 49.12B 18.98B 202B 19.21B 18.81B 740B
More financial data * Estimated data

Company Profile

Logo Quest Diagnostics Incorporated
Quest Diagnostics Incorporated is the world's leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows: - testing and diagnostic services (97%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services; - other (3%).
Employees
50,500
Sector
Healthcare Facilities & Services
Calendar
07-06 - Détachement de
More about the company

Quotes

Date Price Change Volume
18/06/25 179.78 $ +0.46% 618,901
17/06/25 178.95 $ -1.71% 871,882
16/06/25 182.07 $ +1.03% 989,119
13/06/25 180.21 $ +0.65% 1,028,465
12/06/25 179.04 $ +1.16% 743,182

Delayed Quote Nyse, June 18, 2025 at 09:10 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
AAA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
179.78USD
Average target price
183.92USD
Spread / Average Target
+2.30%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. DGX Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition